Prestige Consumer Healthcare Q1 2027 Earnings Report

Prestige Consumer Healthcare EPS Results

• Actual EPS: $0.98
• Consensus EPS: $0.89
• Beat/Miss: Beat by +$0.09
• One Year Ago EPS: $0.90

Prestige Consumer Healthcare Revenue Results

• Actual Revenue: $265.71 million
• Expected Revenue: $253.02 million
• Beat/Miss: Beat by +$12.69 million
• YoY Revenue Growth: +6.50%

Prestige Consumer Healthcare Announcement Details

• Quarter: Q1 2027
• Date: 8/6/2026
• Time: Before Market Opens
• Conference Call Date: Thursday, August 6, 2026
• Conference Call Time: 8:30AM ET

Prestige Consumer Healthcare (NYSE:PBH), Inc. is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy). Prestige distributes its products primarily in the United States and Canada through supermarket, drug store, mass merchandise, dollar, club and e-commerce channels, and selectively in other markets through export partnerships.

Formed through a series of strategic acquisitions of established consumer healthcare names, Prestige Consumer Healthcare has grown by integrating well-known OTC brands under a centralized commercial and operational platform. The company is headquartered in Tarrytown, New York, and leverages a focused R&D and regulatory support team to drive incremental innovation across its brand portfolio. Tony Long has served as President and Chief Executive Officer since December 2019, leading initiatives to expand Prestige’s market presence and enhance its category leadership.

Prestige Consumer Healthcare Q1 2027 Earnings Call Transcript

Key Takeaways

• Positive Sentiment: Q1 revenue rose 6.5% to $265.7 million, with organic growth of 3.2% driven by GI brands such as Dramamine and Fleet, skincare led by Compound W, and strength in TheraTears and Debrox. Adjusted EPS increased to $0.98, while adjusted free cash flow reached a quarterly record of $83.7 million.
• Positive Sentiment: Management raised fiscal 2027 guidance to $1.290 billion-$1.315 billion in revenue and $4.55-$4.65 in adjusted EPS, primarily reflecting the acquisitions of Breathe Right and LaCorium. Adjusted free cash flow is now expected to be at least $270 million, with year-end leverage projected below 4 times.
• Positive Sentiment: The Breathe Right portfolio, expected to generate approximately $200 million in annual revenue, is largely integrated and offers potential growth through marketing, innovation, sports applications, and international expansion. LaCorium adds approximately $40 million of annualized revenue and strengthens Prestige’s therapeutic skincare presence in Australia.
• Negative Sentiment: Clear Eyes sales remain materially constrained by supply issues at the Pillar5 manufacturing facility; the brand currently represents less than 3% of company sales versus a much higher historical level. Management expects output to improve in the second half, but rebuilding inventory, shelf space, product assortment, and consumer engagement is expected to take multiple years.
• Negative Sentiment: Management expects a modest organic revenue decline in the second quarter because retailer order timing benefited Q1, while gross margin declined 120 basis points year over year in Q1 due mainly to transportation costs and product mix. Higher interest and amortization expenses related to the acquisitions are also expected to weigh on near-term earnings.

Presentation

[Operator]

Good day. Thank you for standing by. Welcome to the quarter one 2027 Prestige Consumer Healthcare Inc earnings conference call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star one one again. Please be advised that today's conference call is being recorded. I would now like to hand the conference call over to your first speaker today, Phil Terpolilli, Vice President, Investor Relations and Treasury Business Development. Please go ahead.

[Phil Terpolilli, VP of Investor Relations and Treasury Business Development at Prestige Consumer Healthcare Inc]

Thanks, operator. Thank you to everyone who has joined today. On the call with me are Ron Lombardi, our Chairman, President, and CEO, and Chris Sacco, our CFO and COO. On today's call, we'll review our first quarter fiscal 2027 results, discuss our increased full-year outlook, and then take questions from analysts. A slide presentation accompanies today's call. It can be accessed by visiting prestigeconsumerhealthcare.com, clicking on the investor's link, and then on today's webcast and presentation. Remember, some of the information contained in the presentation today includes non-GAAP financial measures. Reconciliations to the nearest GAAP financial measures are included in our earnings release and slide presentation. In today's call, management will make forward-looking statements around risks and uncertainties, which are detailed in a complete safe harbor disclosure on page two of the slide presentation that accompanies the call. These are important to review and contemplate.

[Phil Terpolilli, VP of Investor Relations and Treasury Business Development at Prestige Consumer Healthcare Inc]

Business environment uncertainty remains heightened due to supply chain constraints, high inflation, and geopolitical events which have numerous potential impacts. This means results could change at any time, and the forecasted impact of risk considerations is the best estimate based on the information available as of today's date. Further information concerning risk factors and cautionary statements are available in our most recent SEC filings and our most recent Company 10-Q that was released this morning. I'll now hand it over to our CEO, Ron Lombardi. Ron?

[Ron Lombardi, Chairman, President, and CEO at Prestige Consumer Healthcare Inc]

Thanks, Phil. Thanks to everyone for joining us on a busy earnings day. While we are just at the start of our fiscal year, we've completed two acquisitions that are now positioned for long-term success, and we'll walk through both of them shortly. Our business exceeded sales and earning expectations in the first quarter, a testament to our long-term brand-building strategy and the strength of our diversified portfolio. We also delivered record adjusted free cash flow, providing additional flexibility for disciplined capital allocation moving forward. With that, let's begin with our first quarter highlights on slide four. Sales of approximately $266 million increased 6.5%, reflecting broad-based strengths across the portfolio.

[Ron Lombardi, Chairman, President, and CEO at Prestige Consumer Healthcare Inc]

Growth was led by GI, where Dramamine and Fleet continued to deliver long-term consumption gains as well as strong performance in skincare led by Compound W. TheraTears and Debrox also posted solid growth, helping offset Clear Eyes sales that were below our expectations. Results also benefited from retailer order timing, which Chris will discuss in more detail. The quarter also included approximately $6 million of revenue from the Breathe Right portfolio acquisition. Our strong top-line performance translated into solid earnings and free cash flow. Gross margin was largely in line with expectations and adjusted EPS increased to $0.98. Adjusted free cash flow reached a quarterly record of $83.7 million, further supporting our ability to deploy capital in ways that enhance shareholder value. One of these deployment priorities is M&A, and since our May call, we completed two acquisitions.

[Ron Lombardi, Chairman, President, and CEO at Prestige Consumer Healthcare Inc]

The Breathe Right portfolio closed on June 12th, and the acquisition of LaCorium in Australia closed on July 1st. I'll discuss our integration progress and the strategic value each brings to Prestige. Our strong cash flow generation is also enabling us to invest in Pillar5, our sterile ophthalmic manufacturing facility, which will help support additional long-term eye care capacity. Now, let's turn to slide five and review the key principles supporting our expected long-term recovery of Clear Eyes. At a high level, we remain focused on the actions we believe will best support Clear Eyes and return the brand to its leadership position within the eye care category. There are three key elements to this strategy. First, we continue to invest in our recently acquired Pillar5 facility. These investments are designed to strengthen long-term supply capabilities while maintaining the high-quality standards we expect across our portfolio.

[Ron Lombardi, Chairman, President, and CEO at Prestige Consumer Healthcare Inc]

Second, a key objective for the facility is to support demand while improving supply consistency versus current levels. As we discussed in May, achieving that objective requires actions during fiscal 2027 that will continue to create some output variability in the first half of the year, as we experienced in Q1 and expect again in Q2. Looking ahead, we believe the facility is positioned for greater stability in the second half, supporting sequential improvements in eye care shipments. Third, as the historical unit share leader in eye care, Clear Eyes has unique volume requirements where we believe in-house manufacturing provides an important strategic advantage. As a result, we expect to further expand capacity at Pillar5 to fully support these long-term demand requirements and return Clear Eyes to its leading market position. Now, let's turn to slide seven and review our recent acquisitions.

[Ron Lombardi, Chairman, President, and CEO at Prestige Consumer Healthcare Inc]

We are pleased to have closed both the Breathe Right portfolio and LaCorium Health acquisitions. Each transaction brings distinct strengths that we believe will enhance our business over the long term. Starting with Breathe Right, the portfolio is expected to generate approximately $200 million in annual revenue. The majority comes from the flagship Breathe Right brand, where we see multiple opportunities for long-term growth that I'll discuss in a moment. The business also brings a strong financial profile, with growth and EBITDA margins that are accretive to Prestige. In addition, it supports our long-term sales and earnings growth algorithm while generating tax benefits that enhance future free cash flow. Less than 60 days after closing, we have successfully completed all major integration milestones.

[Ron Lombardi, Chairman, President, and CEO at Prestige Consumer Healthcare Inc]

As of this week, the business is largely integrated into our operations, running through our systems and our warehouse network, with retailers ordering Breathe Right along with our existing brands. Turning to LaCorium Health, the business is expected to contribute approximately $40 million in annualized revenue, with the majority generated in Australia. Its Dermal Therapy brand holds a leading position in therapeutic skincare categories, including eczema and cold sore treatments. We believe the brand is well-positioned for continued growth and will support the organic growth objectives of our International segment. In July, we welcomed LaCorium's employees into our Care Pharma office, making for a seamless transition given they were already located in the same building outside Sydney, Australia. The broader integration effort will proceed methodically over the balance of the year.

[Ron Lombardi, Chairman, President, and CEO at Prestige Consumer Healthcare Inc]

Over time, we also expect to realize additional synergies through distributor optimization, sales integration, and other operating efficiencies that should further enhance profitability. In summary, we've added two highly strategic businesses to our portfolio. The Breathe Right integration is largely complete, while LaCorium will continue to be integrated over the coming quarters. In both cases, our focus is on establishing a strong foundation for long-term growth and value creation. Now, let's turn to slide eight and discuss how these acquisitions further strengthen our portfolio. One of Prestige's core strengths is the diversity of our portfolio. The diversity helps reduce reliance on any single brand or category while allowing us to allocate resources towards the most attractive growth opportunities and to consistently execute against our long-term growth algorithm. As shown on the right side of the slide, these acquisitions further enhance that diversification.

[Ron Lombardi, Chairman, President, and CEO at Prestige Consumer Healthcare Inc]

On a pro forma basis, our portfolio is now even more balanced across eight categories. With the addition of Breathe Right, we've created a new wellness, sleep, and other category, which is primarily comprised of Breathe Right and represents a low teens percentage of a pro forma revenue. LaCorium's Dermal Therapy brand further strengthens our skincare category, and we've also updated several category names to better reflect the consumer need states they address. Now, let's turn to slide nine and discuss the growth opportunities we see for Breathe Right. With roots dating back to the 1990s, Breathe Right is an iconic category-defining brand with consumer awareness exceeding 90%. Given that strong foundation, we see several drivers of long-term growth.

[Ron Lombardi, Chairman, President, and CEO at Prestige Consumer Healthcare Inc]

As shown on the left side of the slide, Breathe Right has successfully done this through campaigns such as Strip On. Looking ahead, we believe social media marketing initiatives can further strengthen brand engagement and drive household penetration. Second is innovation, shown in the center of the slide. At Prestige, we rely on consumer insights to identify opportunities that can meet evolving consumer needs while expanding categories. We expect Breathe Right to be no exception. Recent launches demonstrate this potential. Breathe Right Menthol, introduced in 2025, combines improved breathing with the added benefit of an aromatic scent. Breathe Right Sport, which is launching now, expands the brand into the sports category with a sweat-resistant strip designed to help improve airflow during exercise. Finally, International expansion remains an attractive opportunity. Breathe Right is sold in more than 20 countries with a strong presence in Western Europe, Australia, and Japan.

[Ron Lombardi, Chairman, President, and CEO at Prestige Consumer Healthcare Inc]

We see opportunities to drive growth through the same marketing and innovation initiatives I just described while also benefiting from geographic expansion and long-term synergies across our global portfolio. In summary, Breathe Right is a category leader with an iconic brand, a strong foundation, and multiple avenues for sustained long-term growth. We look forward to updating you on our progress in the quarters ahead. With that, I'll turn the call over to Chris to review our financials.

[Chris Sacco, CFO and COO at Prestige Consumer Healthcare Inc]

Thanks, Ron. Good morning, everyone. Let's turn to slide 11 and review our first quarter fiscal 2027 financial results. As a reminder, the information in today's presentation includes certain non-GAAP information that is reconciled to the closest GAAP measure in our earnings release. Q1 revenue of $265.7 million grew 6.5% from $249.5 million in the prior year, and 3.2% excluding the effects of foreign currency and the acquisition of the Breathe Right portfolio. Adjusted EBITDA grew 5.5% versus the prior year, mostly tracking the sales growth. Adjusted diluted EPS increased approximately 3% versus the prior year, as the revenue increase was partially offset by higher interest expense from the acquisition. Let's turn to slide 12 for details around these consolidated results. As I just highlighted, our Q1 fiscal 2027 revenues increased 3.2% organically versus the prior year.

[Chris Sacco, CFO and COO at Prestige Consumer Healthcare Inc]

By segment, North America segment revenues increased 4.2%, excluding FX and the Breathe Right portfolio acquisition. As Ron highlighted, the biggest category increases were in GI, highlighted by continued strength in Fleet and Dramamine, and Dermatological, thanks to strong growth in Compound W. In Ear and Eye Care, as we anticipated, Clear Eyes supply continued to be volatile and was constrained in Q1, leading to a decline in brand revenue. This was more than offset by strength in the TheraTears and Debrox brands, which highlights the benefits of our portfolio diversity, even within individual product categories. We also continue to experience strong double-digit consumption growth in e-commerce. Q1 benefited from some continued order volatility in e-commerce at the expense of Q2, and this is reflected in the Q2 sales outlook Ron will discuss later. International segment revenues decreased 2.1% versus the prior year on an organic basis.

[Chris Sacco, CFO and COO at Prestige Consumer Healthcare Inc]

As we expected in our outlook, we continued to see positive consumption trends, but sales were affected by the timing of distributor orders. For the full year, we still expect a return to the segment organic revenue long-term growth target of 5% or more. Revenues from the Breathe Right portfolio acquisition totaled $5.9 million. Total company adjusted gross margin of approximately 55% in the first quarter was largely as anticipated. Flat sequentially, but down 120 basis points versus the prior year, primarily due to higher transportation costs and mix. Following the inclusion of acquisitions, we now anticipate adjusted gross margin of just over 57% for both Q2 and the full year. Advertising and marketing came in at $34.7 million or 13% of sales in Q1, down versus the prior year due to the timing of marketing programs.

[Chris Sacco, CFO and COO at Prestige Consumer Healthcare Inc]

For fiscal 2027 as well as Q2, we now anticipate an A&M rate of approximately 14.5% of sales. Adjusted G&A expenses were 11.5% of sales in Q1. For the full year, we now anticipate adjusted G&A of approximately 10% as a percent of sales, thanks to the scale associated with additional acquisition revenue. Adjusted diluted EPS of $0.98 increased versus last year's diluted EPS of $0.95. Ron will discuss our earnings outlook shortly, and we've detailed the assumed components and other line items at the end of the slide presentation. These include higher interest and amortization expenses in the balance of the year of approximately $100 million and $33 million respectively, as well as a similar tax rate and share count to prior assumptions. Let's turn to slide 13 and discuss cash flow and capital allocation.

[Chris Sacco, CFO and COO at Prestige Consumer Healthcare Inc]

In Q1, we generated $83.7 million in adjusted free cash flow, largely driven by the timing of working capital. We continue to maintain industry-leading free cash flow and now expect to generate at least $270 million of adjusted free cash flow in fiscal 2027 due to the inclusion of the new acquisitions. At June 30th, our net debt was approximately $2 billion. We purchased the Breathe Right portfolio on June 12th, funded with a new seven-year Term Loan B. Combined with cash on-hand, the new term loan also funded the LaCorium transaction, which closed on July 1st after quarter end. Executing these market actions, we also took the opportunity to price $400 million of new unsecured notes, replacing existing notes that were coming due. This funded on July 15th.

[Chris Sacco, CFO and COO at Prestige Consumer Healthcare Inc]

Following these actions, our earliest debt maturity is now 2031. We have reestablished pre-payable debt, which we intend to begin paying down over the balance of the fiscal year. With that, I'll turn it back to Ron.

[Ron Lombardi, Chairman, President, and CEO at Prestige Consumer Healthcare Inc]

Thanks, Chris. Let's turn to slide 14 and wrap things up. We are encouraged by our first quarter results and remain confident in the outlook we previously provided for our legacy business. The updated guidance shown on this page reflects the addition of the Breathe Right portfolio and LaCorium acquisitions, along with the related financing impacts Chris just discussed. For fiscal 2027, we now expect revenues of $1.290 billion-$1.315 billion while maintaining our expectation for organic revenue growth of 1%-3%, unchanged from our prior outlook. The increase in reported revenue versus our previous guidance is entirely driven by the Breathe Right and LaCorium acquisitions, which we expect will contribute approximately $190 million of revenue this year. For the second quarter, we expect revenue of $328 million-$331 million, including the contribution from both acquisitions.

[Ron Lombardi, Chairman, President, and CEO at Prestige Consumer Healthcare Inc]

Given retailer order timing that benefited the first quarter, we would expect a modest organic revenue decline in the second quarter. We continue to expect organic revenue growth for the first half of the fiscal year. For adjusted diluted EPS, we now anticipate $4.55-$4.65 for the full year. The increase versus our prior outlook is entirely attributable to the acquisitions, which bring attractive financial profiles, including strong gross margins and lower G&A as a percentage of sales. For our second quarter, we expect adjusted diluted EPS of approximately $1.06-$1.08. We expect adjusted free cash flow of $270 million or more and a year-end leverage ratio of just below 4x. We will remain disciplined in reducing debt throughout fiscal 2027, which will further strengthen our balance sheet and provide additional flexibility for future capital deployment opportunities that can maximize shareholder value.

[Ron Lombardi, Chairman, President, and CEO at Prestige Consumer Healthcare Inc]

In summary, we're off to a solid start to the year. We delivered strong first-quarter results, remain confident in the outlook for our legacy business, and are excited about the opportunities ahead with Breathe Right and LaCorium. Together, these acquisitions are expected to add more than 20% to our annualized revenue base while providing additional scale, diversification, and long-term value creation opportunities for Prestige. With that, I'll open it up for questions. Operator?

[Operator]

Thank you. At this time, we will conduct the question-and-answer session. As a reminder, to ask a question, you will need to press star one one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. Please stand by while we compile the Q&A roster. Our first question comes from Susan Anderson with Canaccord Genuity. Please go ahead. Your line is now open.

[Susan Anderson, Analyst at Canaccord Genuity]

Hi. Good morning. Thanks for taking my questions. Nice job on the quarter. If you could give us an update on the long-term growth of the two acquisitions. Are you still expecting 10% total growth with contribution obviously from those two over the next several years? I don't think I saw it, how much are the two acquisitions adding to earnings also for the year with the updated outlook? Thanks.

[Ron Lombardi, Chairman, President, and CEO at Prestige Consumer Healthcare Inc]

Good morning, Susan. Ron here. Let me start with the long-term outlook for the two acquisitions. We're about 60 days or so just under for the Breathe Right portfolio and 30 days or so for LaCorium. So far we continue to be very optimistic about the opportunity for the brands and the businesses. As we get into them, we continue to see all the opportunities that we believed were there during the diligence and continue to point you to the outlook that we gave back in May for the long-term outlook for the business. We're in early days here, but to continue to feel really good about the opportunities. Maybe Chris will talk about the-

[Chris Sacco, CFO and COO at Prestige Consumer Healthcare Inc]

Yeah, Susan, hey, good morning. It's Chris. The acquisitions, obviously higher sales growth projected for the year. It's about three points of EPS growth. The range that we provided on the sales line is in line combined with the stub period in Q1 with what we'd expect in the long-term numbers that Ron just shared. EPS is a bit of timing. It's the timing of the stub period, some committed A&M from the sellers prior to our ownership, the impact of the debt paydown in the future and how that will compound over time, just the timing of sales in the near term. A little bit of near-term noise. It's temporary, but we still feel good as we did when we made these acquisitions that will drive sales and profitability for each of the brands as we reduce debt.

[Chris Sacco, CFO and COO at Prestige Consumer Healthcare Inc]

As Ron says, you put that together, you get back to the long-term algo we presented back in May for the three-year CAGRs.

[Susan Anderson, Analyst at Canaccord Genuity]

Okay, great. Maybe if you could, I don't know if I heard you mention the women's health business. Just curious how that performed in the quarter with Monistat and Summer's Eve, are you expecting any new launches there for the rest of the year? Thanks.

[Ron Lombardi, Chairman, President, and CEO at Prestige Consumer Healthcare Inc]

Our women's healthcare businesses continue to make progress. Monistat continues to be fairly steady, continues to have steady or growing share. As we talked about on past calls, the category there has seen some decline over the last few years. For Summer's Eve, we continue to look at long-term new product opportunities and launches. The Ultimate Odor Protection franchise continues to do really well, and we will have additional products launched over the next couple of years as well.

[Susan Anderson, Analyst at Canaccord Genuity]

Okay, great. Thanks so much. Good luck the rest of the year.

[Ron Lombardi, Chairman, President, and CEO at Prestige Consumer Healthcare Inc]

Thank you, Susan.

[Operator]

Thank you. Our next question comes from Rupesh Parikh with Oppenheimer company. Please go ahead. Your line is now open.

[Rupesh Parikh, Analyst at Oppenheimer]

Good morning, and thanks for taking my question. Just going back to the acquisitions, just from an accretion perspective. I know, obviously, timing may be slightly different, but as you look at the acquisitions, is the accretion still in the same ballpark of what you guys thought before for Breathe Right? I think LaCorium there was not much assumed initially. Thank you.

[Chris Sacco, CFO and COO at Prestige Consumer Healthcare Inc]

That's right, Rupesh. You're correct on LaCorium. For Breathe Right, we talked about an annualized rate of about $0.25 of accretion, right? In a normal environment, I would say we absolutely still support that. You'll be a couple pennies as you look at the stub period below that. Again, we expect some variability during the first couple of quarters. Haven't really done an acquisition where we didn't see some initial volatility, particularly as we undo some things maybe the sellers had put in place before the closing process. I mentioned sales timing, I mentioned A&M a bit ago, and then just the timing of how quickly we'll pay down debt, which we'll be prioritizing this year.

[Rupesh Parikh, Analyst at Oppenheimer]

Okay, great. On the gross margin outlook, 57%, obviously very strong. I think there's benefits from the M&A as well. Just curious, in the environment right now, what type of cost pressures are you guys seeing in the business? With these acquisitions, do you expect an improvement in gross margins as we go into next year? Just overall thinking of longer-term opportunities on the margin front with the new M&A.

[Chris Sacco, CFO and COO at Prestige Consumer Healthcare Inc]

Yeah. Rupesh, on the growth margin revised guide up, it's entirely based on the acquisitions. We're holding our base guide for gross margin. It's been in line with our expectations. The increase is primarily year-over-year related to diesel. We factored that in, no change to the base. Over time, we'll of course always look to increase our gross margin. Remember, it will be no different for the acquisitions, that we're managing to a low to mid-30s EBITDA margin. To the extent we get cost saving, we have cost saving programs in place. We'll look to put that back into the business and higher levels of A&M over time.

[Rupesh Parikh, Analyst at Oppenheimer]

Great. Maybe one last question for Ron. Commentary was positive just on consumption during the quarter. Consumer environment is still uncertain. Have you guys seen any changes out there? Just curious just overall what you're seeing in the consumer environment front.

[Ron Lombardi, Chairman, President, and CEO at Prestige Consumer Healthcare Inc]

In our categories, we continue to see fairly stable consumption. As I mentioned in the prepared remarks, we continue to see strong growth in the GI brands, Dramamine and Fleet. Skin, we're doing well in. Again, as we've talked about for about a year now, the big thing we're seeing is that consumers are looking for value, and it's impacting where they shop. We continue to see channel shifts. We had another particularly strong growth in dot com and in mass again this quarter. We continue to see strong growth in those value channels or where price shopping is easy.

[Rupesh Parikh, Analyst at Oppenheimer]

Great. Thank you, I'll pass along.

[Ron Lombardi, Chairman, President, and CEO at Prestige Consumer Healthcare Inc]

Okay. Thanks, Rupesh.

[Operator]

Thank you. Our next question comes from Jon Andersen with William Blair. Thank you. Your line is now open.

[Jon Andersen, Analyst at William Blair]

Yeah, good morning. Thanks for the questions. Could you quantify the order timing benefit in the first quarter, and I guess that'll reverse out in the second quarter?

[Chris Sacco, CFO and COO at Prestige Consumer Healthcare Inc]

Yeah, Jon. It was just about two points of growth for the quarter. Again, that's why we're trying to focus folks back to the first half where we still expect organic growth in total.

[Jon Andersen, Analyst at William Blair]

First half underlying growth kind of on plan. It's just a bit of a shift from quarter to quarter.

[Chris Sacco, CFO and COO at Prestige Consumer Healthcare Inc]

That's correct.

[Jon Andersen, Analyst at William Blair]

Okay, great. Could you give us a little bit more of an update on, I guess, Clear Eyes and maybe where it sits today relative to its kind of prior peak run rate and how some of the operational initiatives at Pillar5 are progressing, and what kind of ramp to think about there as you think about getting Clear Eyes back to its leadership position over the next, I don't know, couple of years?

[Ron Lombardi, Chairman, President, and CEO at Prestige Consumer Healthcare Inc]

Yeah. Let me start there, Jon. Clearly, the Clear Eyes franchise is down significantly from its peak levels a few years ago, right? Again, driven by product availability. We're two quarters in. At the end of June, we had owned Pillar5 for just two quarters. We've got a multifaceted program in place to stabilize the facility and better position it for long-term product availability to support the brand. We've made a number of changes over the last six months, starting with investment to better position the infrastructure, some investment in the equipment. We've also made significant changes in the management and leadership change in the team there. Clearly, that's something we're not going to talk about ahead of time. Last quarter, we weren't going to talk about management team changes publicly ahead of getting them in place.

[Ron Lombardi, Chairman, President, and CEO at Prestige Consumer Healthcare Inc]

We've transitioned out a significant amount of consultants that the previous owners had in place. We've made changes in management and recently appointed a new general manager for the facility who's a long-term employee that we feel really good about. It's not just one thing. It's a whole bunch of initiatives that we continue to get behind us. I think as we said today, we expect to see improving levels of output for the second half of the year as we continue to focus on getting the initiatives behind us.

[Phil Terpolilli, VP of Investor Relations and Treasury Business Development at Prestige Consumer Healthcare Inc]

Jon, it's Phil. I think you asked about where Clear Eyes sits today versus the high watermark. As we talked about last quarter, because of the supply challenges we've seen, it represents less than 3% of sales today. Certainly, we expect to improve that based on the demand that we know is out there and the production changes that Ron's talking about. A lot of runway ahead, and we think it's an opportunity.

[Jon Andersen, Analyst at William Blair]

That 3% is with the acquisition revenue?

[Phil Terpolilli, VP of Investor Relations and Treasury Business Development at Prestige Consumer Healthcare Inc]

Yes.

[Jon Andersen, Analyst at William Blair]

Do you have anything on, as you rebuild capacity or improve output, there are other steps, obviously, that probably need to be taken to get back to that leadership position. Working with retailers, reestablishing shelf space, activating the consumer again. In your experience, how long does that aspect of this tend to take?

[Ron Lombardi, Chairman, President, and CEO at Prestige Consumer Healthcare Inc]

We've talked about it being multi-year, Jon, and that plan really is unchanged. There's kind of four pieces to it. First is to develop consistent and high-quality supply. The second would be to start to rebuild safety stocks for ourselves and at retailers, so that as we have variability in the future from supply, we won't see a hiccup in sales or out of stock. Third would be to get back to our full SKU offering. Right now, if you get out to the shelf, you'll see that we focused on Base Red and Max Red. Fourth would be to get back to investing in marketing and advertising campaigns, to get back to connect the brand with consumers who have been out there looking for it. A number of steps that we'll be thoughtful about executing over the next couple of years.

[Jon Andersen, Analyst at William Blair]

Great. Just one more, if I could. You've done two acquisitions here in close proximity. Are you confident that you can integrate both of these and hit the ground running? I just sometimes think about integration risk, the bandwidth of the team to manage and brand build, and go after some of the opportunities around both at the same time. Thanks.

[Ron Lombardi, Chairman, President, and CEO at Prestige Consumer Healthcare Inc]

Yeah. As we said in the prepared remarks today, the Breathe Right portfolio, that business is essentially integrated into Prestige. Just this Monday, we flipped the switch, and the whole business is in our system. Purchase orders to the supply base, to receiving product, to orders from our customers and making shipments to the retailers is happening. The marketing folks that we took on from the seller are here with our marketing team. We've got sales people that we've taken on that are out in the field working with the customers. Breathe Right is integrated, and we're into continuing to focus on growth plans for that business. For LaCorium, we've made sure we've given ourselves enough of a runway so that we're not competing for resources internally as we were dealing with the bigger Breathe Right.

[Ron Lombardi, Chairman, President, and CEO at Prestige Consumer Healthcare Inc]

We've got a bit of a longer runway that will work on the integration of that business over the rest of the fiscal year. Again, and we've emphasized this a number of times, we have the huge advantage of LaCorium being in the same office building that Care is. Literally, just a couple of floors up, and those people have moved down to the Care floor. The organization is integrated, and we're making progress on that. This is something that Prestige actually does very well, and our integration planning begins during diligence. It's not just what are you getting, but how are you going to integrate it so you hit the ground running, to use your words. Breathe Right's in a great place, and we're continuing to move forward on LaCorium.

[Jon Andersen, Analyst at William Blair]

Great. Thank you very much.

[Operator]

Thank you. As a reminder, to ask a question, you will need to press star one one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. Our next question comes from, excuse me one second, Keith Devas with Jefferies. Please go ahead, your line is now open.

[Keith Devas, Analyst at Jefferies]

Hey, good morning. Thanks for taking the question. Just going back higher level to the retailer inventories. I'm curious where you guys think there are now. We've heard from some peers that there's been some volatility or choppiness in the quarter, higher level, also, just how are you thinking about adjusting your operations and spend to account for this ongoing volatility or choppiness?

[Ron Lombardi, Chairman, President, and CEO at Prestige Consumer Healthcare Inc]

Good morning, Keith. In terms of retailer inventory levels for our categories, we haven't seen the builds and the destock that you're hearing others talk about in other categories. That hasn't been the driver in some of the order pattern volatility that we've seen. We talked a little bit about it in Q4, we talked about it in Q1. That just seems to be planning and resource driven by really one main customer. Again, we're able to deal with whatever the flow is and the peaks and valleys of that. Consumption is good, inventory levels are stable, and we're just managing around the timing impact of that from quarter to quarter.

[Keith Devas, Analyst at Jefferies]

Okay, great. I think you commented, one of the acquisitions is pretty much integrated and other will soon be. You also mentioned some synergies that are coming down the road. If you could just give us some context on what those synergies are, where they're coming from, how we should think about them, and maybe it's a longer-term question, but yeah, just how you see that materializing over time.

[Ron Lombardi, Chairman, President, and CEO at Prestige Consumer Healthcare Inc]

Yeah, it's more of a year to two runway for the synergies that we've talked about associated with LaCorium. There's opportunities and benefits to synergize the sales forces between the two organizations. We think we can adopt some resources from both of the businesses to be in a better place. We think there'll be some marketing opportunities for some synergies that'll give us some pools to reinvest, and then the supply chain as well. No one big area, like we've seen in other acquisitions that we've primarily done in the U.S., where we essentially just bolt on a brand into our existing infrastructure. This one's nuanced with a number of different areas that we'll get at over the next year or two. First order of business is to get it integrated into our systems and processes.

[Keith Devas, Analyst at Jefferies]

Okay, great. Thank you. I'll pass it on.

[Ron Lombardi, Chairman, President, and CEO at Prestige Consumer Healthcare Inc]

Thank you.

[Operator]

Thank you. Our next call comes from Anthony Lebiedzinski with Sidoti. Please go ahead. Your line is now open.

[Anthony Lebiedzinski, Analyst at Sidoti]

Thank you and good morning, everyone, and thanks for taking the questions. Nice start to the fiscal year. Just wondering if there was any notable pricing benefit in the quarter and given the pressures as it relates to higher diesel costs and other costs. Are you looking to perhaps raise prices? How should we think about those things?

[Chris Sacco, CFO and COO at Prestige Consumer Healthcare Inc]

Hi, Anthony. It's Chris. Minimal price in the quarter. As we look to our fiscal 2027 outlook, I would say about a quarter of the growth is projected to be price.

[Anthony Lebiedzinski, Analyst at Sidoti]

Got it. Okay.

[Chris Sacco, CFO and COO at Prestige Consumer Healthcare Inc]

That's showing inflationary pressures, including diesel.

[Anthony Lebiedzinski, Analyst at Sidoti]

Okay, thanks for that. Okay. As it relates to Breathe Right, you talked about focusing longer term on brand building. From my understanding, that brand does more advertising marketing compared to the core business. Are you looking to spend even more than that? When you talk about brand building, can you give us some examples as to what you think you'll be doing here going forward after you get past the near-term programs that already are in place?

[Ron Lombardi, Chairman, President, and CEO at Prestige Consumer Healthcare Inc]

Yeah. For the Breathe Right business, it's got higher gross margins and higher A&M and slightly higher contribution margin or EBITDA margins in our base business. Plenty of room for advertising and marketing spend. The brand has been on a path to move and expand from kind of illness occasions, think of congestions and cold and allergies, to that better breathing, better sleep, better wellness positioning. The spending and the programs have kind of been in the base business. We wouldn't anticipate a need to increase the spending levels from historic levels, Anthony.

[Anthony Lebiedzinski, Analyst at Sidoti]

Understood. Okay. All right. Well, thank you very much and best of luck.

[Ron Lombardi, Chairman, President, and CEO at Prestige Consumer Healthcare Inc]

Thank you.

[Operator]

Thank you. I am showing no further questions at this time. I would now like to turn the call back over to Ron Lombardi for closing remarks. Please go ahead, Ron.

[Ron Lombardi, Chairman, President, and CEO at Prestige Consumer Healthcare Inc]

Thank you, operator, and thanks everyone for joining us today, and your continued interest in Prestige. We are pleased with our strong start to fiscal 2027 and remain focused on executing our strategy, integrating our recent acquisitions, and creating long-term value for our shareholders. We appreciate your time today and look forward to updating you next quarter. Have a great day.

[Operator]

Thank you for your participation in today's conference. This does conclude the program. You may now disconnect the call.

Participants

Executives

• Phil Terpolilli, VP of Investor Relations and Treasury Business Development
• Ron Lombardi, Chairman, President, and CEO
• Chris Sacco, CFO and COO

Analysts

• Susan Anderson, Analyst at Canaccord Genuity
• Rupesh Parikh, Analyst at Oppenheimer
• Jon Andersen, Analyst at William Blair
• Keith Devas, Analyst at Jefferies
• Anthony Lebiedzinski, Analyst at Sidoti